Phase 2 Trial of New Mesothelioma Therapy, Using ImmunoGen’s ADC Technology, Getting Underway
News
ImmunoGen, Inc. recently announced it has earned a milestone payment with Bayer’s initiation of a global Phase 2 clinical trial of anetumab ravtansine (BAY 94-9343) as a potential treatment for mesothelioma. ... Read more